News
PCVX
59.47
+0.97%
0.57
Vaxcyte (PCVX) On Tighter Phase 3 Timing And New Hires Looks Undervalued
Simply Wall St · 19h ago
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
The Motley Fool · 4d ago
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
The Motley Fool · 4d ago
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The Motley Fool · 4d ago
Weekly Report: what happened at PCVX last week (0831-0904)?
Weekly Report · 5d ago
Vaxcyte narrows timing for pivotal VAX-31 data to late October
Seeking Alpha · 6d ago
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX)
Simply Wall St · 6d ago
Vaxcyte Appoints Luis Jodar, David McAvoy To Leadership Team; Accelerates Phase 3 VAX-31 Timeline
NASDAQ · 09/04 07:53
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
TipRanks · 09/03 22:40
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
TipRanks · 09/03 20:30
Vaxcyte narrows previously communicated VAX-31 guidance
TipRanks · 09/03 20:30
*Vaxcyte Sees VAX-31 OPUS-1 Topline Data by End of October
Dow Jones · 09/03 20:12
*Vaxcyte Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Dow Jones · 09/03 20:11
*Vaxcyte Names Luis Jodar as Medical Chief
Dow Jones · 09/03 20:11
Press Release: Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Dow Jones · 09/03 20:05
Press Release: Vaxcyte Appoints Chief Medical -2-
Dow Jones · 09/03 20:05
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Barchart · 09/03 15:05
Weekly Report: what happened at PCVX last week (0824-0828)?
Weekly Report · 08/31 09:18
Weekly Report: what happened at PCVX last week (0817-0821)?
Weekly Report · 08/24 09:18
Vaxcyte: Not Enough Safety Margin With Current Price
Seeking Alpha · 08/18 17:59
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.